Stay updated with breaking news from சுவாச பாதை தொற்று. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stewardship / Resistance Scan for Sep 23, 2021 umn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umn.edu Daily Mail and Mail on Sunday newspapers.
ANALYSIS: How misinformation 'fuelled' second wave of COVID-19 spread in Nigeria thecable.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecable.ng Daily Mail and Mail on Sunday newspapers.
Global Amoxicillin Market to Exhibit at a 1.5% CAGR during the forecast period 2020-2027 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
email article Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, 40% of patients treated with rituximab had sustained complete remission after ≥16 weeks off prednisone, as compared with 10% of patients randomized to MMF. Rituximab treatment was associated with a significantly reduced need for glucocorticoids and with a dramatic reduction in the number of disease flares. Quality-of-life scores improved more with rituximab, but MMF was associated with fewer serious adverse events (SAEs), reported Victoria Werth, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues in the ....
Share this article Share this article ResearchAndMarkets.com s offering. The Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 850 respiratory deals. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals. ....